scholarly journals In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea?

2019 ◽  
Vol 74 (6) ◽  
pp. 1591-1594 ◽  
Author(s):  
Susanne Jacobsson ◽  
Clive Mason ◽  
Nawaz Khan ◽  
Paul Meo ◽  
Magnus Unemo
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Treatment Option ◽  
Mechanism Of Action ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Future Treatment ◽  
Future Treatment Option

scholarly journals High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae

2020 ◽  
Vol 75 (11) ◽  
pp. 3244-3247
Author(s):  
Susanne Jacobsson ◽  
Clive Mason ◽  
Nawaz Khan ◽  
Paul Meo ◽  
Magnus Unemo
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Small Molecule ◽  
Mechanism Of Action ◽  
Vitro Activity ◽  
In Vivo Studies ◽  
In Vitro Activity ◽  
Agar Dilution ◽  
High Level

Abstract Background The rising incidence of antimicrobial resistance in Neisseria gonorrhoeae may result in untreatable gonorrhoea in certain circumstances and development of novel antimicrobials is urgently needed. Objectives To evaluate the in vitro activity of a novel small-molecule antimicrobial with a new mechanism of action, DIS-73285, against a large geographically, temporally and genetically diverse collection of clinical N. gonorrhoeae isolates and reference strains, including various types of high-level resistant, MDR and XDR gonococcal isolates (n = 262). Methods MICs (mg/L) of DIS-73285 were determined by agar dilution and by Etest for ceftriaxone, cefixime, azithromycin, ciprofloxacin, ampicillin, spectinomycin and tetracycline. Results DIS-73285 was substantially more potent than any of the currently or previously used therapeutic antimicrobials, with MICs ranging from ≤0.001 to 0.004 mg/L, and the MIC50, MIC90 and modal MIC all ≤0.001 mg/L (lowest MIC tested). No correlation with the MICs of DIS-73285 and the MICs of any of the currently or previously used antimicrobials was observed. Conclusions The novel chemotype, small-molecule antimicrobial DIS-73285, demonstrated high in vitro potency against all tested N. gonorrhoeae isolates. Further in vitro and in vivo studies, evaluating efficacy, resistance emergence, pharmacokinetic/pharmacodynamic parameters, toxicity and safety, should be conducted to evaluate DIS-73285 as a therapy specifically for urogenital and extra-genital gonorrhoea.

scholarly journals In vitro activity of 14 antimicrobial agents against Neisseria gonorrhoeae from Spain.

1987 ◽  
Vol 63 (3) ◽  
pp. 215-216
Author(s):  
M C Lozano ◽  
J C Palomares ◽  
R Prados ◽  
E J Perea
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Antimicrobial Agents ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

2017 ◽  
Vol 72 (5) ◽  
pp. 1355-1358 ◽  
Author(s):  
Dina A. Boikov ◽  
Jeffrey B. Locke ◽  
Kenneth D. James ◽  
Ken Bartizal ◽  
Jack D. Sobel
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Candida Spp
Sign in / Sign up

Export Citation Format

Share Document